Antengene Corporation Limited 722.F Stock

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. The company also develops other clinical stage assets, such as ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with patients with high-risk myelodysplastic syndromes; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma; ATG-037, an CD73 inhibitor for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; and ATG-031 an anti-CD24 monoclonal antibody. In addition, its pre-clinical stage assets consist of ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Antengene Corporation Limited was founded in 2016 and is headquartered in Shanghai, China.